Why Dendreon Corporation Shares Soared

Dendreon shares soar for a change after reporting its fourth-quarter earnings results. Is this move sustainable or the perfect exit point for shareholders?

Mar 3, 2014 at 12:15PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Dendreon (NASDAQ:DNDN), a biopharmaceutical company developing immunotherapeutic options for cancer patients, soared as much as 20% after it reported fourth-quarter earnings results before the opening bell.

So what: For the quarter, Dendreon reported an 8% decline in year-over-year sales of metastatic prostate cancer immunotherapy vaccine Provenge to $74.8 million as its adjusted loss, thanks to steep cost cuts and its second restructuring in a matter of two years, fell by 44% to $25.4 million, or just $0.17 per share. By comparison, Wall Street had expected only $72.9 million in revenue, with a wider loss of $0.24 per share. Dendreon's community oncology segment grew by 19% from the prior year, and the number of large accounts hit 100, up from 94 in the sequential third quarter. The company also notes that it plans to make Provenge available in Europe, beginning with the U.K. and Germany, in cities with larger populations and easier access to health care so as to minimize its rollout costs.

Now what: It was nice to see Dendreon not drop a bomb on shareholders for once during earnings season, but its cash burn continues to be a serious concern. It ended the year with $199.4 million in cash, cash equivalents, and investments compared to $429.8 million at this time last year. Obviously, its costs will shrink as Provenge sales begin in Europe and its second restructuring reduces its expenses, but there still is no timetable on when it'll be cash flow positive.

Also, competition in the metastatic prostate cancer space is very fierce. It could be tough for Dendreon to gain traction following phase 3 data from Medivation's (NASDAQ:MDVN) Xtandi, which demonstrated marked superiority over the placebo in a pre-chemo setting. Xtandi has really stood apart from the competition in recent months and could become the therapy of choice for most physicians in late-stage prostate cancer, making Dendreon's turnaround even tougher to accomplish. For now, I'm perfectly happy watching this situation unfold from the sidelines, and I'd suggest you do the same.

Dendreon might be off to the races today, but it'll likely have a hard time keeping up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers